The company began in 1963 as a weekly weight-loss support group meeting with 400 attendees Read more at straitstimes.com.

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Pharmaceutical company Novo Nordisk is waiting on federal approval to sell its blockbuster GLP-1 weight-loss treatment as a pill.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

However, Wegovy has lost significant market share to rival Eli Lilly‘s (NYSE:LLY) Zepbound, because it is seen as a better, more efficacious GLP-1 drug. Zepbound’s active ingredient, tirzepetide, is ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Hims & Hers Health appoints former Amazon executive Nader Kabbani as its chief operating officer. The telehealth-consultation platform on Monday said Kabbani will oversee operations as the company ...